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SUMMARY. This study aims to evaluate the implementation and operation of a pharmacovigilance pro-
gram in the pharmaceutical industry in Brazil, taking as a tool a questionnaire with closed questions. The
survey was carried out between the second quarter of 2009 and the first quarter of 2010. From 181 phar-
maceutical companies that received the questionnaire, 7.18 % did not answer, but reported that they did
not have a pharmacovigilance program or said that it was confidential company information, 27.62 %
have contributed to the survey by answering the questions. Of these, 82 % said they already have a pro-
gram of pharmacovigilance and 18 % said the program was under implementation. Moreover, companies
considered small businesses represent the majority of which are in the deployment phase of their pharma-
covigilance programs. Considering results and comparing with the number of notifications received on the
reports from Sistema de Notificações em Vigilância Sanitária (Notifications System in Health Surveil-
lance), it was observed that pharmaceutical companies represent a small portion when compared to hospi-
tals and notifying pharmacies.
